

Charity Registration No. 1098584

Company Registration No. 4691176 (England and Wales)

**THE BRITISH TRANSPLANTATION SOCIETY**  
**ANNUAL REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 OCTOBER 2020**

# THE BRITISH TRANSPLANTATION SOCIETY

## LEGAL AND ADMINISTRATIVE INFORMATION

---

<b>Trustees</b>	Mr N Torpey Professor S J Wigmore Miss L Burnapp Dr S V Griffin	(Appointed 4 March 2020)
<b>Secretary</b>	Dr S V Griffin	
<b>Charity number</b>	1098584	
<b>Company number</b>	4691176	
<b>Registered office</b>	Chester House 68 Chestergate Macclesfield Cheshire SK11 6DY	
<b>Auditor</b>	Mitchell Charlesworth LLP 3rd Floor 5 Temple Square Temple Street Liverpool Merseyside L2 5RH	
<b>Bankers</b>	Bank of Scotland plc West End Office 14-16 Cockspur Street London SW1Y 5BL	

---

# THE BRITISH TRANSPLANTATION SOCIETY

## CONTENTS

---

	Page
Trustees' report	1 - 7
Independent auditor's report	8 - 10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13 - 23

---

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)

### ***FOR THE YEAR ENDED 31 OCTOBER 2020***

---

The trustees (who are also the directors of the company for the purposes of company law) present their report and the audited financial statements of the charity for the year ended 31 October 2020. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

#### **Objectives and activities**

The principal activities of the company are to advance transplantation by:-

- the study of the surgical, clinical, biological, ethical and social problems of tissue and organ transplantation;
- facilitating contact between persons interested in transplantation;
- making new knowledge available to any person for the general good of the community;
- retaining intellectual property rights over its activities; and
- pursuing other matters relevant to transplantation.

By being the voice of transplantation for all solid organs within the UK, the Society aims to benefit the general public and patients by ensuring that up-to-date knowledge and best practice in transplantation is shared widely between all professional groups, that research that advances the understanding of transplantation is supported and encouraged and that the media is engaged to promote the benefits of organ donation and transplantation and to ensure accurate representation of topical news items.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2020

---

### Achievements and performance

Kingston Smith Association Management (KSAM) continued to provide support as the BTS secretariat during 2019/20.

The Society had an active year in 2019/20, consolidating activities in line with the strategic plan, originally published in 2015 and reviewed in June 2017. Key priorities are to:

- Advance scientific and clinical research and innovation relevant to the practice of transplantation.
- Influence public opinion and operational strategy relevant to transplantation.
- Promote excellence in professional standards and ethics across the multi-disciplinary transplant community.
- Contribute to the advancement of transplantation, from organ donation to long-term follow up, to maximise patient and graft outcomes for all organs. The activities of the Society are aligned to these strategic aims, which are reviewed biennially.

No area of clinical care has escaped the appalling impact of the COVID 19 pandemic, and transplantation is no exception to this. The contribution of the Society to the response of the transplant community is detailed below.

Enhanced Council representation across all organ groups has continued to encourage engagement with the Society, increase membership and integration between all professional groups, including those that have been traditionally under-represented within BTS. The Chapter of Nurses is increasingly active and offers membership support for more academic activities.

The Society has four affiliated organisations: The Herrick Club, Solid Organ Transplant Pharmacists Association, British Liver Transplant Group and the British Urology Transplant Society (which became an affiliated society in 2019). The Society continues to welcome applications in line with the policy agreed in 2016.

The Executive and Council continue to represent the Society's views to a number of organisations including: the NHS Blood and Transplant advisory and strategy groups and National Organ Donation Committee; The Association of Surgeons of Great Britain and Ireland; The National Institute of Health and Clinical Excellence; The Renal Association; The British Renal Society; the UK Renal Registry; the Renal Transplant Clinical Reference Group for NHS England; the Kidney Health Partnership and other professional organisations. During the past four years, the BTS has been invited to co-host an increasing number of joint sessions at other professional society meetings and Congresses, for example UK Kidney Week (run by the Renal Association and British Renal Society). A policy is now in place to engage in these events, whilst ensuring that there is mutual benefit to all Societies involved.

The redevelopment of the public-facing website in 2016 was welcomed by members and has enhanced the profile of the Society. The website has been crucial over the last year in dissemination of regular updates in relation to SARS-CoV-2. This is maintained and managed by Thumb Design who delivered the redesign. At that time, it was agreed that KSAM would retain operational control of the more complex members' area of the website and update it to ensure that it was fit for purpose. This was successfully completed in 2017 and the continuity of these essential membership functions has been maintained throughout. The website provides updates on events of interest, a link to the Executive Committee newsletters and links to minutes of relevant meetings at which the society has representation.

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

---

The BTS appointed a Communications Officer for the first time in 2016 on a sessional basis. This provided a useful point of contact to facilitate responses to media and news enquiries in a timely and consistent manner and in developing social media communications and policies for the Society. The current Officer will be standing down and the Council is considering her replacement.

The Society continued its on-going work drafting and revising standards and guidelines either alone or in collaboration with other societies for the clinical management of various aspects of transplantation. The Guidelines and Standards produced by the Society are accredited by NICE and have developed a global reputation. 2019 saw the publication of the Guidelines for the Management of Pancreas and Islet Transplantation. The current Chair of the committee is standing down and his successor appointed in early 2020.

The Society has an active bursary scheme, which supports a maximum of 10 non-consultant members up to £500 each to attend national and international meetings and educational events. The bursary scheme has been reviewed and criteria for applications revised to improve awareness of the scheme and to ensure equitable allocation and representation across all sectors of the Society. Seven bursaries were awarded in 2019/20.

#### Strategic Report

##### Review of activities

##### *Annual General Meeting*

The Annual General Meeting (AGM) of the Society took place on Wednesday 4 March 2020 during the 23rd Annual Congress in Belfast. The results of the 2020 elections to the Council and Sub-Committees were announced. The election was run on-line by Civica Election Services (formerly known as the Electoral Reform Services). 269 of 606 eligible members voted, representing a turnout of 44.4%. Seven Council positions (one Executive) were included in the election, and seven sub-committee positions. The following changes to the Trustees took place at the AGM:

Stood down at end of term:

Dr R Hilton

Appointed:

Dr N Torpey (to treasurer)

The next AGM will be held on Tuesday 23 February 2021.

##### *Annual Congress*

The 23rd Annual Congress of the Society was held between 6 and 8 March 2020 at the International Convention Centre, Belfast. Over the three days, 549 delegates attended (compared to 851 in 2019, when the Congress was held jointly with NHSBT, and 574 in 2018, our last stand-alone Congress). A total of 233 abstracts were submitted for presentation (compared to 296 in 2019). 226 abstracts were accepted, 49 for oral presentations and 177 as posters (37 moderated, 140 standard).

The overall theme of the Congress was "It's good to talk: collaboration in transplantation" and was opened by Mary Jo McCann, Director of Visitor Servicing, Visit Belfast. We were delighted to welcome Professor Steve Yule to the opening plenary session when he spoke about teamworking and human factors.

The Congress opened with a new session, the BTS Dragon's Den: clinical trials and research for trainees in transplantation. Six studies were shortlisted for presentation to the "Dragons" - four clinical trials and two cohort studies. There were three educational sessions, focussed on Collaborative Research, Organisational and Systems Collaboration and Clinical MDT Collaboration. The two industry-sponsored symposia were "Matching donors and recipients: are we there yet" and "How can we achieve optimum outcomes for highly sensitised kidney transplant candidates?"

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

---

There were seven submissions for the Sir Roy Calne Award for the best peer-reviewed paper. The winner was Zubir Ahmed from Guy's and St Thomas' for his paper "Prophylaxis of Wound Infections Antibiotics in Renal Donation (POWAR): A UK Multicentre Double-Blind Placebo Controlled Randomised Trial", published in the Annals of Surgery (272 (1):65-71, 2020).

The Medawar Medal for the best clinical abstract presented was awarded to Siobhan McKay, University Hospitals Birmingham NHS Foundation Trust for her paper "Normothermic Machine Perfusion of the Liver to Enable transplantation in difficult recipients (NAPLES)", and for the best science abstract to Hannah Wilkinson, King's College London, for her paper "Thrombin fine tunes innate immune cell function in models of localised antigen".

The next Congress was originally confirmed as being held between 24 and 26 February 2021 in Manchester. Due to the on-going impact of the COVID-19 pandemic, the decision was taken to move to an on-line platform. The revised virtual Congress will take place on 24 and 25 February 2021.

#### **Research Network development**

The inaugural meeting of the UK Organ Donation and Transplantation Research Network was held at the Royal Free Hospital on 11 February 2020, jointly sponsored by the BTS and NHSBT. All UK transplant units were represented. The morning board meeting established the terms of reference for the Network and discussed key metrics and future measurements of success. The afternoon focussed on Patient and Public Engagement, with discussions of patient priorities for future research. The Network has matured over the year, appointed a project manager (funded by NHSBT and Kidney Research UK) and supported 14 grant applications.

#### **Living Donor Forum and Winter Ethics Symposium**

The combined Living Donor Forum and Winter Ethics Symposium was held in York on 28 November 2019. The theme was Expanding the Living Donor Pool: Incentives and Beyond. The Hoffenberg Lecture was delivered by Dr Julian Koplin, Research Fellow with the Biomedical Ethics Research Group, University of Melbourne.

#### **Education**

Several members of the society have contributed to the online educational resources of the European Society of Organ Transplantation (ESOT).

#### **COVID-19**

The majority of UK transplant units closed for a variable period at the start of the pandemic and there was an urgent need to provide information to the transplant community about the safety of donation and potential risk to the incident and prevalent recipient populations. The society has worked closely with NHSBT to ensure the provision of timely, accurate and consistent information. Early in the pandemic the clinical guidelines were updated every two weeks, reflecting the speed at which knowledge was increasing. We contributed to two webinars explaining the background to the pandemic and the impact on transplantation services. More recently, the BTS has provided representation to the vaccine implementation group established by the Renal Association.

#### **NHSBT Strategy Document**

Following stakeholder events held across the UK in 2018, the BTS Executive and many Council members have contributed to the NHSBT strategy document - Organ Donation and Transplantation: Meeting the Need. A ten-year vision for organ donation and transplantation in the United Kingdom.

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2020

---

### How the Charity operates for the public benefit

By being the voice of transplantation for all solid organs within the UK, the Society aims to benefit the general public and patients by ensuring that:

1. Up-to-date knowledge and best practice in transplantation are shared widely between all professional groups and throughout the wider transplant community.
2. Research that advances the understanding of transplantation is supported and encouraged.
3. The media is engaged to promote the benefits of organ donation and transplantation and to ensure accurate representation of topical news items.

### Financial review

The results for the year and the charity's financial position at the end of the year are shown in the attached accounts.

The statement of financial activities shows a net deficit for the year of £6,711 (2019: surplus of £33,081) and total reserves now stand at £262,099 (2019: £268,809).

### Reserves policy

The Council reviews its reserves policy on a yearly basis.

The Council has established that the target level of general funds (being unrestricted and undesignated) in the Society is £120,000. These are required to: -

- Protect against a fall in annual unrestricted income. The Society is particularly dependent upon its corporate members.
- Accommodate the eventuality of a loss at the Society's Annual Congress and other activities.
- Permit continued funding of Society bursaries and fellowships.
- Cover administration and support costs without which the charity could not function.

The current level of general funds remains above the reserve.

The reserves policy will continue to be monitored by the trustees.

### Investment Powers and Policy

Under the Memorandum and Articles of Association, the charity has the power to invest in any lawful way the trustees wish.

### Risk review

The trustees continually assess the major risks to which the Society is exposed, particularly those related to the operations and finances of the organisation and are satisfied that systems are in place to mitigate the Society's exposure to the major risks.

The trustees regard the major risks to be the loss of one or more corporate sponsors, and having to cancel the Annual Congress requiring reimbursement of the income generated resulting in a deficit from costs that will have been incurred and which would not be recoverable.

### Future developments

The Society will continue to be the voice of solid organ transplantation in the United Kingdom and aim to deliver and review its Strategic aims to reflect the views and requirements of the membership. It has committed to exploring the options for increasing patient and public engagement in its future activities.



# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2020

---

### Structure, governance and management

The charity is constituted as a company limited by guarantee and governed by its Memorandum and Articles of Association. There is no share capital and every member of the company undertakes to contribute to the assets of the company while he/she is a member or within one year after he/she ceases to be a member, such amounts as may be required, not exceeding £1.00 in the event of winding up. The company is registered under the Charities Act 2011 (No. 1098584) and as such is not liable to income tax, corporation tax and capital gains tax.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Mr N Torpey	(Appointed 4 March 2020)
Dr R Hilton	(Resigned 4 March 2020)
Professor S J Wigmore	
Miss L Burnapp	
Dr S V Griffin	

### Appointment of trustees

The trustees of the Society are appointed at general meetings, each individual appointment being for a term of office not exceeding the number of successive years as specified in the Rules.

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

### Organisation

The business of the Society is managed by the Trustees, who may exercise all the powers of the Society. The Trustees of the Society shall be the President, Vice President, Treasurer and General Secretary.

The Council consists of the four Trustees together with elected councillors and other persons co-opted to Council for specific tasks or in support of the work of the Council. The Council has responsibility for the strategic direction of the Society and is the forum for discussion regarding specific issues, which may affect the Society or its members. The Council also has responsibility regarding the planning and management of the annual meeting of the Society. Some of the organisation of this meeting is delegated to the Congress Organising Committee but final decisions rest with the trustees.

The Society has established Committees to manage specified aspects of the Society's activities. There is a minimum of Ethics, Education, Clinical Trials and Research and Standards Committees. Each Committee has a chairperson who is either co-opted by Council or elected by the members for a period of three years. The responsibilities of the Committees and the Committee chairpersons are set out in the rules of the Society. No Committee shall act independently of the Council and final authority, including overall financial matters of the Society, rests with the trustees.

### Trustee induction and training

A standard induction procedure and training is provided to all new trustees taking up office.

# THE BRITISH TRANSPLANTATION SOCIETY

## TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED) FOR THE YEAR ENDED 31 OCTOBER 2020

---

### Statement of trustees' responsibilities

The trustees, who are also the directors of The British Transplantation Society for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Auditor

In accordance with the company's articles, a resolution proposing that Mitchell Charlesworth LLP be reappointed as auditor of the company will be put at a General Meeting.

### Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report, including the strategic report, was approved by the Board of Trustees.



**Dr S V Griffin**

Trustee

Dated: 23 February 2021

# THE BRITISH TRANSPLANTATION SOCIETY

## INDEPENDENT AUDITOR'S REPORT

### TO THE TRUSTEES OF THE BRITISH TRANSPLANTATION SOCIETY

---

#### Opinion

We have audited the financial statements of The British Transplantation Society (the 'charity') for the year ended 31 October 2020 which comprise the statement of financial activities, the balance sheet and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 October 2020 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

#### Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

# THE BRITISH TRANSPLANTATION SOCIETY

## INDEPENDENT AUDITOR'S REPORT (CONTINUED)

### TO THE TRUSTEES OF THE BRITISH TRANSPLANTATION SOCIETY

---

#### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the trustees' report, which includes the directors' report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

#### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

#### **Responsibilities of trustees**

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

# THE BRITISH TRANSPLANTATION SOCIETY

## INDEPENDENT AUDITOR'S REPORT (CONTINUED)

### TO THE TRUSTEES OF THE BRITISH TRANSPLANTATION SOCIETY

---

#### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

*Mitchell Charlesworth*

**Philip Griffiths (Senior Statutory Auditor)**  
**for and on behalf of Mitchell Charlesworth LLP**

23 February 2021

**Chartered Accountants**  
**Statutory Auditor**

3rd Floor  
5 Temple Square  
Temple Street  
Liverpool  
Merseyside  
L2 5RH

# THE BRITISH TRANSPLANTATION SOCIETY

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 OCTOBER 2020**

		Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
	Notes						
<b>Income from:</b>							
Donations and legacies	3	1,503	-	1,503	839	-	839
Charitable activities	4	334,652	-	334,652	405,960	-	405,960
Investments	5	592	-	592	921	-	921
<b>Total income</b>		<b>336,747</b>	<b>-</b>	<b>336,747</b>	<b>407,720</b>	<b>-</b>	<b>407,720</b>
<b>Expenditure on:</b>							
Charitable activities	6	337,340	6,117	343,457	372,941	1,698	374,639
Gross transfers between funds		-	-	-	(2,377)	2,377	-
<b>Net (expenditure)/income for the year/</b>							
<b>Net movement in funds</b>		<b>(593)</b>	<b>(6,117)</b>	<b>(6,710)</b>	<b>32,402</b>	<b>679</b>	<b>33,081</b>
Fund balances at 1 November 2019		205,617	63,192	268,809	173,215	62,513	235,728
<b>Fund balances at 31 October 2020</b>		<b>205,024</b>	<b>57,075</b>	<b>262,099</b>	<b>205,617</b>	<b>63,192</b>	<b>268,809</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

# THE BRITISH TRANSPLANTATION SOCIETY

## BALANCE SHEET

AS AT 31 OCTOBER 2020

	Notes	2020 £	£	2019 £	£
<b>Fixed assets</b>					
Intangible assets	13		-		900
<b>Current assets</b>					
Debtors	16	70,239		90,487	
Cash at bank and in hand		263,951		281,753	
		<u>334,190</u>		<u>372,240</u>	
<b>Creditors: amounts falling due within one year</b>	17	<u>(72,091)</u>		<u>(104,331)</u>	
Net current assets			262,099		267,909
<b>Total assets less current liabilities</b>			<u>262,099</u>		<u>268,809</u>
<b>Income funds</b>					
Restricted funds	19		57,075		63,192
Unrestricted funds			205,024		205,617
			<u>262,099</u>		<u>268,809</u>

The financial statements were approved by the Trustees on 23 February 2021



Mr N Torpey  
Trustee

Company Registration No. 4691176

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 OCTOBER 2020

---

#### 1 Accounting policies

##### Charity information

The British Transplantation Society is a private company limited by guarantee incorporated in England and Wales. The registered office is Chester House, 68 Chestergate, Macclesfield, Cheshire, SK11 6DY. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The nature of the charity's operations and principal activities are described in the Trustees' Report on pages 1 to 7 of these financial statements.

##### 1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

##### 1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

##### 1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

##### 1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Income from charitable activities incorporating membership fees is deferred until entitlement to the income has passed when received in advance.



# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

---

#### 1 Accounting policies

(Continued)

No amount is included in the financial statements for volunteer time in line with the SORP (FRS 102).

Investment income is earned through holding assets for investment purposes such as bank deposits and largely comprises interest. Interest income is recognised using the effective interest method.

#### 1.5 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

- Expenditure on charitable activities includes both direct costs and support costs relating to these activities.
- Other expenditure represents those items not falling into the categories above.

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a pro-rata basis consistent with the use of the resources.

#### 1.6 Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website	33% per annum
---------	---------------

#### 1.7 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment	20% per annum
-----------	---------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2020

---

### 1 Accounting policies

(Continued)

#### 1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

#### 1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Basic financial liabilities**

Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

##### **Derecognition of financial liabilities**

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

#### 1.11 Taxation

The charity is an exempt charity within the meaning of Schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1, Schedule 6 of the Finance Act 2010 and therefore meets the definition of a charitable company for UK corporation tax purposes.

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

#### 1 Accounting policies

(Continued)

##### 1.12 Provisions

Provisions are recognised when the charity has a legal or constructive present obligation as a result of a past event, it is probable that the charity will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in net income/(expenditure) in the period in which it arises.

#### 2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

#### 3 Donations and legacies

	Unrestricted funds	Unrestricted funds
	2020 £	2019 £
Donations and gifts	1,503	839

#### 4 Charitable activities

	Subscriptions & memberships 2020 £	Congress & meetings 2020 £	Total 2020 £	Subscriptions & memberships 2019 £	Congress & meetings 2019 £	Total 2019 £
Corporate subscriptions	50,000	-	50,000	31,667	-	31,667
Individual memberships	59,770	-	59,770	56,775	-	56,775
Annual Congress income	-	212,276	212,276	-	301,674	301,674
Other meetings income	-	12,606	12,606	-	15,844	15,844
	<u>109,770</u>	<u>224,882</u>	<u>334,652</u>	<u>88,442</u>	<u>317,518</u>	<u>405,960</u>

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2020

### 5 Investments

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Interest receivable	592	921

### 6 Charitable activities

	Grants payable	Congress & other meetings	Total 2020	Grants payable	Congress & other meetings	Total 2019
	2020	2020		2019	2019	
	£	£	£	£	£	£
Annual Congress	-	209,359	209,359	-	249,881	249,881
Other meetings	-	16,096	16,096	-	14,729	14,729
	-	224,328	225,455	-	264,610	264,610
Grant funding of activities (see note 7)	4,978	-	4,978	1,918	-	1,918
Share of support costs (see note 8)	-	101,664	101,664	-	96,491	96,491
Share of governance costs (see note 8)	-	11,360	11,360	-	11,620	11,620
	4,978	338,479	343,457	1,918	372,721	374,639
<b>Analysis by fund</b>						
Unrestricted funds	2,079	335,261	337,340	1,554	371,387	372,941
Restricted funds	2,899	3,218	6,117	364	1,334	1,698
	4,978	338,479	343,457	1,918	372,721	374,639

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2020

### 7 Grants payable

	Grants payable 2020 £	Grants payable 2019 £
BTS Bursary	2,899	364
Medawar Medal	2,079	1,554
	<u>4,978</u>	<u>1,918</u>

-

### 8 Support costs

	Support costs £	Governance costs £	2020 £	Support costs £	Governance costs £	2019 £
Depreciation	900	-	900	8,760	-	8,760
IT and software	10,964	-	10,964	6,713	-	6,713
Printing, postage and stationery	1,491	-	1,491	1,372	-	1,372
Legal and professional	-	-	-	300	-	300
Secretariat	64,788	-	64,788	63,520	-	63,520
Bank charges	3,772	-	3,772	3,671	-	3,671
Bad debts	518	-	518	2,000	-	2,000
Irrecoverable VAT	19,231	-	19,231	10,155	-	10,155
Audit fees	-	6,045	6,045	-	6,522	6,522
Trustee expenses	-	1,447	1,447	-	1,266	1,266
Council member expenses	-	3,868	3,868	-	3,832	3,832
	<u>101,664</u>	<u>11,360</u>	<u>113,024</u>	<u>96,491</u>	<u>11,620</u>	<u>108,111</u>
Analysed between						
Charitable activities	<u>101,664</u>	<u>11,360</u>	<u>113,024</u>	<u>96,491</u>	<u>11,620</u>	<u>108,111</u>

### 9 Net movement in funds

	2020 £	2019 £
Net movement in funds is stated after charging/(crediting)		
Fees payable to the company's auditor for the audit of the company's financial statements	6,045	6,522
Amortisation of intangible assets	<u>900</u>	<u>8,760</u>

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

---

#### 10 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year. The total amount of reimbursed expenses was £1,447 (2019 £1,266) made to four trustees (2019 - four). At 31st October 2020 the balance outstanding was £Nil (2019 £Nil).

#### 11 Employees

There were no employees during the year.

#### 12 Taxation

The company is a registered charity and no provision for taxation is considered necessary.

#### 13 Intangible fixed assets

	Website £
<b>Cost</b>	
At 1 November 2019 and 31 October 2020	28,250
	<hr/>
<b>Amortisation and impairment</b>	
At 1 November 2019	27,350
Amortisation charged for the year	900
	<hr/>
At 31 October 2020	28,250
	<hr/>
<b>Carrying amount</b>	
At 31 October 2020	-
	<hr/>
At 31 October 2019	900
	<hr/>

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 OCTOBER 2020

### 14 Tangible fixed assets

	Equipment £
<b>Cost</b>	
At 1 November 2019	4,422
At 31 October 2020	4,422
<b>Depreciation and impairment</b>	
At 1 November 2019	4,422
At 31 October 2020	4,422
<b>Carrying amount</b>	
At 31 October 2020	-
At 31 October 2019	-

### 15 Financial instruments

	2020 £	2019 £
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	306,956	313,774
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	13,959	10,731

### 16 Debtors

	2020 £	2019 £
<b>Amounts falling due within one year:</b>		
Trade debtors	42,885	31,621
Prepayments and accrued income	27,354	58,866
	70,239	90,487

Bad debts totalling £518 were provided for during the year (2019 £2,000).

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

**FOR THE YEAR ENDED 31 OCTOBER 2020**

### 17 Creditors: amounts falling due within one year

	Notes	2020 £	2019 £
Other taxation and social security		5,697	733
Deferred income	18	52,435	92,867
Trade creditors		8,140	3,409
Accruals and deferred income		5,819	7,322
		<u>72,091</u>	<u>104,331</u>

### 18 Deferred income

	2020 £	2019 £
Other deferred income	<u>52,435</u>	<u>92,867</u>

Deferred income comprises membership deferrals and income relating to the 2021 Annual Congress and other meetings.



# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 OCTOBER 2020

#### 19 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 November 2018	Resources expended	Transfers	Balance at 1 November 2019	Resources expended	Balance at 31 October 2020
	£	£	£	£	£	£
Clinical Trials Fund	19,521	-	-	19,521	-	19,521
Hoffenberg Memorial Lecture Fund	27,480	(1,334)	346	26,492	(3,218)	23,274
BTS Bursary Scheme	15,512	(364)	2,031	17,179	(2,899)	14,280
	<u>62,513</u>	<u>(1,698)</u>	<u>2,377</u>	<u>63,192</u>	<u>(6,117)</u>	<u>57,075</u>

The Clinical Trials Fund represents income from the National Kidney Research Fund which is available for use by the Clinical Trials sub-committee.

The Hoffenberg Memorial Lecture Fund represents a donation to fund an annual lecture on transplantation in honour of the memory of Sir Raymond Hoffenberg.

The BTS Bursary Scheme balance represents monies previously provided by the pharmaceutical companies, Astellas and Novartis, for a bursary scheme to allow members to attend the American Transplantation Congress and the European Society for Organ Transplantation Congress. The schemes have not been renewed but the companies concerned have allowed the Society to retain the balance of monies to fund future bursaries for attendance at BTS's own meetings.

#### 20 Analysis of net assets between funds

	Unrestricted funds 2020	Restricted funds 2020	Total 2020	Unrestricted funds 2019	Restricted funds 2019	Total 2019
	£	£	£	£	£	£
Fund balances at 31 October 2020 are represented by:						
Intangible fixed assets	-	-	-	900	-	900
Current assets/(liabilities)	205,024	57,075	262,099	204,717	63,192	267,909
	<u>205,024</u>	<u>57,075</u>	<u>262,099</u>	<u>205,617</u>	<u>63,192</u>	<u>268,809</u>

#### 21 Capital commitments

There were no capital commitments at 31st October 2020 (2019 - £Nil).

# THE BRITISH TRANSPLANTATION SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

***FOR THE YEAR ENDED 31 OCTOBER 2020***

---

### **22 Related party transactions**

There were no disclosable related party transactions during the year (2019 - none).

In the opinion of the trustees there is no ultimate controlling party.